- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Shaker Heights Today
By the People, for the People
VION Biosciences Acquires CTL, Expanding Immune Monitoring
The acquisition strengthens VION's functional immune monitoring capabilities.
Apr. 8, 2026 at 12:22pm
Got story updates? Submit your updates here. ›
VION Biosciences, a leading biopharmaceutical company, has announced the successful completion of its acquisition of CTL, a pioneer in functional immune monitoring. This strategic move will allow VION to enhance its suite of immune-based diagnostic and therapeutic solutions, further solidifying its position as a key player in the rapidly evolving field of immunology.
Why it matters
The acquisition of CTL by VION Biosciences represents a significant milestone in the company's growth strategy, as it aims to bolster its capabilities in the critical area of functional immune monitoring. This integration will enable VION to offer more comprehensive and advanced solutions to its clients, ultimately benefiting patients and driving innovation in the biopharmaceutical industry.
The details
VION Biosciences, a leading biopharmaceutical company, has successfully completed the acquisition of CTL, a pioneer in functional immune monitoring. This strategic move will allow VION to enhance its suite of immune-based diagnostic and therapeutic solutions, further solidifying its position as a key player in the rapidly evolving field of immunology.
- The acquisition was announced on April 8, 2026.
The players
VION Biosciences
A leading biopharmaceutical company that specializes in developing innovative immune-based diagnostic and therapeutic solutions.
CTL
A pioneer in the field of functional immune monitoring, providing advanced technologies and expertise to support the development of new immunotherapies.
The takeaway
The acquisition of CTL by VION Biosciences represents a significant step forward in the company's efforts to strengthen its capabilities in functional immune monitoring, a critical area for the development of innovative immunotherapies and diagnostics. This integration will enable VION to offer more comprehensive and advanced solutions to its clients, ultimately benefiting patients and driving innovation in the biopharmaceutical industry.
